卡格列净与芬特明联合用药用于超重和肥胖非糖尿病人群体重管理:一项随机临床试验
这项26周、2a期、随机、双盲、安慰剂对照、多中心、平行组研究纳入335例超重或肥胖且无2型糖尿病的成人,比较卡格列净300 mg与芬特明15 mg联合用药与安慰剂及两药单药治疗的疗效和安全性;联合用药较安慰剂显著降低体重,且总体耐受良好。
要点
- 第26周时,CANA/PHEN较安慰剂的最小二乘均值体重降幅差为-6.9%(95%CI -8.6至-5.2;P<0.001)。
- CANA/PHEN在达到体重下降≥5%的比例和收缩压降低方面均优于安慰剂。
- CANA/PHEN总体耐受良好,安全性与各单药成分一致。
核心结论
- 在超重或肥胖且无2型糖尿病的个体中,CANA/PHEN使体重出现有意义的下降,且总体耐受良好。
- 需要进一步研究以评估该联合方案用于长期体重管理的潜在用途。
研究设计与样本
- 26周、2a期、随机、双盲、安慰剂对照、多中心、平行组研究,纳入335例18-65岁、BMI≥30至<50 kg/m2或BMI≥27至<50 kg/m2伴高血压和/或血脂异常的超重或肥胖且无2型糖尿病个体。
- 参与者按1:1:1:1随机接受安慰剂、卡格列净300 mg、芬特明15 mg或卡格列净300 mg与芬特明15 mg联合用药,每日口服一次。
- 主要终点为从基线至第26周体重变化百分比;关键次要终点为体重下降≥5%的参与者比例及收缩压自基线变化。
主要发现
- 第26周时,CANA/PHEN较安慰剂的最小二乘均值体重降幅差为-6.9%(95%CI -8.6至-5.2;P<0.001)。
- CANA/PHEN在达到体重下降≥5%方面优于安慰剂。
- CANA/PHEN在收缩压降低方面优于安慰剂。
- CANA/PHEN总体耐受良好,安全性和耐受性特征与各单药成分一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以评估该联合方案用于长期体重管理的潜在用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, aged 18-65 years, BMI ≥30 to <50 kg/m2 or BMI ≥27 to <50 kg/m2 with hypertension and/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss ≥5% and change from baseline in systolic blood pressure. RESULTS: CANA/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference -6.9% [95% CI -8.6 to -5.2]; P < 0.001). CANA/PHEN also provided statistically superior achievement of weight loss ≥5% and reduction in systolic blood pressure compared with PBO. CANA/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components. CONCLUSIONS: CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.
引用
- Hollander P, Bays HE, Rosenstock J, et al. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017. PMID: 28289041. doi:10.2337/dc16-2427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。